Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
For the ProShares Large Cap Core Plus ETF (CSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $55.17 per unit.
With CSM stock trading at a recent price near $45.38 per unit, that means that analysts see 21.57% upside for this ETF looking through to the average analyst targets of the underlying holdings.
Although VLO has traded at a recent price of $57.12 per share, the average analyst target is 42.16% higher at $81.20 per share. Similarly, VIAB has 41.84% upside from the recent share price of $43.24 if the average analyst target price of $61.33 per share is reached, and analysts on average are expecting IVZ to reach a target price of $38.30 per share, which is 41.43% above the recent price of $27.08.
Below is a twelve month price history chart comparing CSM stock to the performances of VLO, VIAB, and IVZ:
Below is a summary table of the current analyst target prices discussed above:
|Name||Symbol||Recent Price||Avg. Analyst 12-Mo. Target||% Upside to Target|
|ProShares Large Cap Core Plus ETF||CSM||$45.38||$55.17||21.57%|
|Valero Energy Corp.||VLO||$57.12||$81.20||42.16%|
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock’s trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on VLO — FREE
Get the latest Zacks research report on VIAB — FREE
Get the latest Zacks research report on IVZ — FREE
More From InvestorPlace
- The 10 Best Healthcare Stocks to Buy Now
- 8 Stocks to Buy Now Before the Market Realizes Their Mistake
- 6 Dividend Stocks to Dodge or Dump